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Abstract
Anniversaries of the identification of three human teratogens (i.e., rubella virus in 1941, 
thalidomide in 1961, and diethylstilbestrol in 1971) occurred in 2011. These experiences highlight 
the critical role that scientists with an interest in teratology play in the identification of teratogenic 
exposures as the basis for developing strategies for prevention of those exposures and the adverse 
outcomes associated with them. However, an equally important responsibility for teratologists is 
to evaluate whether medications and vaccines are safe for use during pregnancy so informed 
decisions about disease treatment and prevention during pregnancy can be made. Several recent 
studies have examined the safety of medications during pregnancy, including antiviral medications 
used to treat herpes simplex and zoster, proton pump inhibitors used to treat gastroesophageal 
reflux, and newer-generation antiepileptic medications used to treat seizures and other conditions. 
Despite the large numbers of pregnant women included in these studies and the relatively 
reassuring results, the question of whether these medications are teratogens remains. In addition, 
certain vaccines are recommended during pregnancy to prevent infections in mothers and infants, 
but clinical trials to test these vaccines typically exclude pregnant women; thus, evaluation of their 
safety depends on observational studies. For pregnant women to receive optimal care, we need to 
define the data needed to determine whether a medication or vaccine is “safe” for use during 
pregnancy. In the absence of adequate, well-controlled data, it will often be necessary to weigh the 
benefits of medications or vaccines with potential risks to the embryo or fetus.
INTRODUCTION
The year 2011 brought some key anniversaries for scientists with an interest in teratology. 
Seventy years ago, in 1941, Norman Gregg, an Australian ophthalmologist, identified 
rubella as a human teratogen after noting a characteristic form of congenital cataracts in 78 
infants, 68 of whom had been born to mothers with rubella during pregnancy (Gregg, 1941). 
Development of a vaccine against rubella and a vaccination program subsequently resulted 
in elimination (defined as absence of ongoing transmission in a geographic area) of rubella 
and congenital rubella syndrome from the United States (Centers for Disease Control and 
Prevention, 2005; Reef and Cochi, 2006). Fifty years ago, data suggesting that thalidomide 
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exposure during pregnancy causes birth defects first became available. In November of 
1961, Lenz presented data on 52 infants born to mothers taking thalidomide during 
pregnancy at a meeting of the German Society for Pediatric Medicine, and he later received 
115 additional reports of similarly affected infants from physicians in Germany, Belgium, 
Sweden, and England (Lenz, 1962). In December of 1961, McBride published a letter in 
Lancet, noting severe abnormalities among offspring born to mothers on thalidomide during 
pregnancy, and asked whether other physicians had seen abnormalities among infants whose 
mothers had taken this medication during pregnancy (McBride, 1961) In a letter to Lancet 
published in early 1962, Lenz reported the specificity of the findings (e.g., an unusual type 
of limb defects, hemangiomata, absent auricles) in the cases he had collected (Lenz, 1962). 
Identification of thalidomide as a teratogen and the resulting decrease in sales of the 
medication resulted in an abrupt decrease in the number of the cases with the characteristic 
limb defects (Običan and Scialli, 2011). Forty years ago, in 1971, Herbst et al. reported a 
new association between maternal diethylstilbestrol use during pregnancy and occurrence of 
adenocarcinoma of the vagina in their daughters 15 to 20 years later in the New England 
Journal of Medicine. The authors compared clinical histories from eight patients who 
presented to New England Hospitals with this rare tumor in their teens and early 20s to those 
from matched controls, and found that seven of eight mothers of the case patients had been 
treated with diethylstilbestrol during pregnancy, compared to none in the control group 
(Herbst et al., 1971). These findings raised the specter of effects of teratogens occurring 
many years after the prenatal exposure (Goodman et al., 2011).
Identification of new human teratogens is a key role for members of the Teratology Society 
and readers of the Birth Defects Research journals because recognition of teratogenicity can 
lead to prevention of birth defects caused by these agents (Običan and Scialli, 2011). 
However, determining whether an agent is a teratogen is not as straightforward as one might 
think. Even some “classic” teratogens such as rubella virus and thalidomide were not 
immediately accepted by the medical community as causes of birth defects (Swan, 1944; 
Warkany, 1988).
An equally important responsibility for researchers and clinicians in teratology is to assess 
the safety of medications and vaccines used during pregnancy. Recent data suggest that 
medications are commonly used during pregnancy. In one study, about half of the pregnant 
women in the United States were taking one or more prescription medications in 2008 
(Mitchell et al., 2011). However, limited data are available on the safety of medications used 
during pregnancy: a recent review of prescription medications approved by the U.S. Food 
and Drug Administration (FDA) from 2000 to 2010 showed that the teratogenic risk was 
undetermined in 97.7% (Adam et al., 2011). In addition, certain vaccines (e.g., against 
influenza and tetanus, diphtheria, and pertussis) are recommended for use during pregnancy 
to protect the mother and/or infant from disease (CDC, 2011a; CDC, 2011b). For women to 
receive optimal care during pregnancy, we need to better define what data are needed to 
determine whether a medication or vaccine is “safe” for use during pregnancy. In addition, 
in the absence of adequate, well-controlled data, it is important to determine how best to 
weigh the benefits of medications or vaccines with potential, but often unknown, risks to the 
embryo or fetus. Another essential concern is to understand how we can communicate these 
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complicated issues to health care providers and pregnant women faced with decisions about 
these exposures during pregnancy (Conover and Polifka, 2011).
Several articles published in the past year have brought these issues to the forefront. For 
example, Pasternak and Hviid (2010a) examined the use of acyclovir, valacyclovir, and 
famciclovir, antiviral medications used to treat herpes simplex and herpes zoster, during the 
first trimester of pregnancy. Using a large nationwide cohort study for births in Denmark 
between January 1996 and September 2008, they compared outcomes of 1804 pregnancies 
exposed to one of these three antiviral medications to outcomes of unexposed pregnancies. 
Forty infants (2.2%) of babies born to mothers taking one of these medications had a major 
birth defect, compared to 2.4% of babies born to unexposed mothers (adjusted prevalence 
odds ratio [POR] of 0.89; 95% confidence interval [CI] 0.65–1.22). However, despite the 
large size of this study, with 1561 women exposed to acyclovir, the most commonly used of 
these medications, an accompanying editorial by Drs. James Mills and Tonia Carter (2010) 
noted that these data are not adequate to rule out this medication as a potential teratogen: 
“From a public health perspective, this study provides fairly strong reassurance that 
acyclovir is not a major cause of birth defects. However, this study leaves a key question 
unanswered – is acyclovir a teratogen?” The authors note that teratogens typically increase 
the risk for certain birth defects, rather than an increase in all birth defects (Mills and Carter, 
2010). Thus, this study, despite its large size, had insufficient power to provide reassurance 
about the safety of these medications.
Proton-pump inhibitors (PPIs) are medications that are frequently used to treat 
gastroesophageal reflux, a common symptom among pregnant women. However, data on the 
use of PPIs during pregnancy are limited. An article by Pasternak and Hviid (2010a), using 
the same nationwide cohort study from Denmark, examined the use of these medications 
during pregnancy, with 3651 pregnancies exposed to any PPI and 1800 exposed to 
omeprazole. Neither exposure to any PPI or to omeprazole was associated with birth defects 
(adjusted POR, 1.10; 95% CI 0.91–1.34 for any PPI; adjusted POR, 1.05; 95% CI, 0.79–1.40 
for omeprazole; Pasternak and Hviid, 2010b). But again, despite these relatively reassuring 
data with large numbers of exposed pregnancies, an accompanying editorial by Dr. Allen 
Mitchell noted that these data were insufficient to ensure safety: “The report on proton-
pump inhibitors…is therefore both timely and important…however, these data provide only 
a broad –and incomplete – overview” (Mitchell, 2010).
Molaard-Nielson and Hviid, using the same Danish dataset and study design, evaluated the 
risk associated with use of certain antiepileptic medications during pregnancy (Mølgaard-
Nielsen and Hviid, 2011). Treatment of epilepsy is challenging because several antiepileptic 
medications (e.g., phenytoin, valproic acid, and carbamazepine) have been associated with 
an increased risk for birth defects. In addition to treating epilepsy, antiepileptic medications 
are increasingly used to treat other conditions, such as migraines and bipolar disorders. 
Several newer-generation antiepileptic medications have become available, but the safety of 
these medications during pregnancy is unknown. The Danish authors focused their analysis 
on these newer-generation medications, including lamotrigine, oxcarbazepine, topiramate, 
gabapentin, and levetiracetam. Based on study of 1532 pregnancies exposed to these 
medications, maternal exposure during pregnancy was not associated with an increased risk 
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for birth defects (adjusted POR, 0.99; 95% CI, 0.72–1.36). Likewise, no increased risk was 
observed for the more frequently used of these medications, lamotrigine (1019 exposed 
women; adjusted POR, 1.18; 95% CI, 0.83–1.68) and oxcarbazepine (393 exposed women; 
adjusted POR, 0.86; 95% CI, 0.46–1.59). The numbers of women exposed to the other 
medications were small, ranging from 108 for topiramate to 58 for levetiracetam, making 
inferences regarding the safety of these medications difficult. Similar to the limitations noted 
for the previous two studies by this group, the numbers of cases exposed, even to the more 
frequently used medications, were insufficient to examine the risk for specific defects. As an 
example, among the 1532 pregnancies exposed to these newer-generation antiepileptic 
medications, only two infants were born with orofacial clefts. The authors appropriately 
noted these limitations and commented that while topiramate, gabapentin, and levetiracetam 
did not seem to be major teratogens, their study was unable to exclude minor to moderate 
increases in the risk for birth defects.
Of note, the article by Mølgaard-Nielsen and Hviid (2011), published in the May 18, 2011, 
issue of the Journal of the American Medical Association, did not include mention of the 
decision posted online in March of 2011 by the FDA to make a labeling change for 
topiramate from Pregnancy Category C (meaning that animal studies suggest a potential 
fetal risk or are lacking and that there are no adequate, well-controlled human studies 
available to assess safety) to Pregnancy Category D (meaning that there is positive evidence 
of human fetal risk, but that the benefits of use may exceed the risks for some women; Food 
and Drug Administration, 2011). The FDA cited data presented in June 2010 at the 
Teratology Society meetings (Hernandez-Diaz et al., 2010) from the North American 
Antiepileptic Drug Pregnancy Registry that suggested that women taking topiramate during 
pregnancy were significantly more likely to have an infant with a cleft, compared to women 
in the general population; two topiramate-exposed infants (0.69%) had an isolated cleft lip, 
compared to an expected prevalence of isolated cleft lip in the general population of around 
0.07%. Similarly, the UK Epilepsy and Pregnancy Register reported a 16-fold increased risk 
for orofacial clefts associated with topiramate exposure during pregnancy, compared to the 
background rate in the population (Hunt et al., 2008).
Concerns about topiramate have also been raised because of its inclusion in combination 
with phentermine as a potential therapy for obesity. This combination treatment, called 
Qnexa, was studied in clinical trials and submitted to the FDA for approval. In those trials, 
this combination was reportedly well tolerated and was associated with significant weight 
loss, making it a promising new treatment for obesity. Given the increasing prevalence of 
obesity in the United States, with more than one third of U.S. women ages 20 to 39 years 
categorized as obese in 2007 to 2008 (Flegal et al., 2010) and the many adverse outcomes 
(including adverse pregnancy outcomes) associated with obesity (Scialli, 2006), a safe and 
effective treatment for obesity would be of great interest to women of childbearing age. 
However, in October 2010, the FDA did not approve the initial application for Qnexa, in 
part because of concerns for an increased risk for oral clefts when used during pregnancy. 
Their review included the epidemiologic data on topiramate exposure during pregnancy 
already cited, in addition to supportive animal data and information from the FDA’s review 
of the Adverse Events Reporting System database, which showed 64 infants with birth 
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defects whose mothers were exposed to topiramate, including 11 infants with cleft lip and/or 
cleft palate (Roberts, 2010). Additional data on the effects of topiramate during pregnancy 
are clearly needed to provide more information on its use as an isolated treatment or used in 
combination with phentermine as a treatment for obesity.
Another event that has recently increased awareness of the need for more data on the safety 
of medications and vaccines during pregnancy is the 2009 H1N1 pandemic, and this 
experience highlights the need to weigh the benefits of medications and vaccines with the 
potential risks. Based on information available from previous pandemics and from seasonal 
influenza, pregnant women were anticipated to be at increased risk for influenzaassociated 
complications (Rasmussen et al., 2008). Thus, pre-pandemic recommendations were 
developed that in a pandemic, pregnant women should receive prompt empiric treatment 
with an antiviral medication (the specific medication to be used was to be based on antiviral 
sensitivity patterns; Rasmussen et al., 2009). It was expected that the benefits of antiviral 
treatment would outweigh the potential, but unknown, risks to the embryo or fetus 
associated with antiviral medication use. Before the pandemic began, data on the use of 
antiviral medications during pregnancy were very limited. For example, data on oseltamivir 
use during pregnancy were limited to 61 reports of oseltamivir-exposed pregnancies during 
the post-marketing period, and data on zanamivir were even more limited – only three 
zanamivir-exposed pregnancies were reported during the clinical trials for this medication 
(Rasmussen et al., 2009). In addition, because influenza vaccine protects not only the 
pregnant mother from influenza, but also her infant, who is not eligible to receive an 
influenza vaccine until 6 months of age (Zaman et al., 2008), it was recommended that 
pregnant women be a priority group to receive a pandemic vaccine, once it became 
available. However, it was recognized that although observational data regarding use of 
seasonal influenza vaccine during pregnancy have been reassuring (Tamma et al., 2009), 
well-controlled studies with sufficient power to assess the risks of individual birth defects 
were not available. In addition, given the increased risk for adverse outcomes associated 
with hyperthermia during pregnancy (Moretti et al., 2005), it was recommended that 
pregnant women with fever receive antipyretic treatment, and after review of the available 
antipyretic medications, acetaminophen was deemed to be the best option (Rasmussen et al., 
2009). However, even for a commonly used medication like acetaminophen, data that would 
ensure safety were not available. Thus, public health recommendations were made based on 
weighing the benefits of treatment or prophylaxis against the potential risks to the embryo or 
fetus.
Data on effects of the 2009 H1N1 pandemic on pregnant women have become available in 
the two years since the pandemic. These data suggest that pregnant women are more than 
four times as likely to be hospitalized, compared to the general population (Jamieson et al., 
2009). In addition, pregnant women made up a disproportionate number of deaths; even 
though pregnant women make up about 1% of the general population, 5% of deaths in the 
early wave of the pandemic were among pregnant women (Jamieson et al., 2009). Deaths 
occurred in all three trimesters, and occurred even in women for whom the only risk factor 
for severe illness was pregnancy. Finally, pregnant women who received antiviral 
medications within the first two days after symptom onset were much less likely to be 
admitted to an intensive care unit or to die (Siston et al., 2010). Since the pandemic, 
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additional data have become available on the safety of influenza medications (Tanaka et al., 
2009; Greer et al., 2010) and of seasonal and monovalent 2009 H1N1 vaccine (Moro et al., 
2011a; Moro et al., 2011b), and all have been reassuring. Based on these data, it seems 
likely that the risks associated with antiviral medications or with influenza vaccine are 
outweighed by the benefits of early treatment or of prevention of influenza for pregnant 
women. However, further data are needed so that risks can be appropriately assessed.
The experience with the 2009 H1N1 pandemic also underscores the difficulty with 
communicating issues regarding benefits and potential risks of medications to health care 
providers and pregnant women. Despite clear public health recommendations for empiric 
treatment of pregnant women with suspected influenza with oseltamivir, treatment was often 
delayed, and as noted previously, delay in antiviral treatment was associated with severe 
outcomes (intensive care unit admission or death; Siston et al., 2010). One reason that likely 
contributed to treatment delays is the reluctance by pregnant women to take medications 
during pregnancy that are perceived as possibly harmful to the embryo or fetus (Lynch et al., 
2011). Despite reassuring data about the safety of influenza vaccine during pregnancy and 
information on the severity of influenza among pregnant women, about 10% of obstetrician-
gynecologists surveyed did not recommend seasonal influenza vaccination in the first 
trimester of pregnancy because of concerns about its safety (Kissin et al., 2011). Educational 
efforts for pregnant women and their health care providers about the benefits and potential 
risks of exposures during pregnancy need to use communication strategies shown to be 
effective (Conover and Polifka, 2011).
The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) is a study 
aimed at improving understanding of the effects of antiviral medications and influenza 
vaccines during pregnancy (Schatz et al., 2011). VAMPSS uses two complementary study 
designs: a prospective cohort identified through the Organization of Teratology Information 
Specialists Research Center at the University of California San Diego and a case-control 
study conducted through the Slone Epidemiology Center at Boston University. The 
prospective cohort arm of the study will compare pregnancy outcomes of women who have 
received an influenza vaccine or antiviral medication to women who were not exposed. A 
wide variety of outcomes can be analyzed, including spontaneous abortion, fetal death, 
preterm birth, small for gestational age, preeclampsia, and presence of a malformation. The 
case-control study design focuses on specific major malformations identified through 
hospitals and birth defects surveillance systems. Mothers of babies with (cases) and without 
(controls) malformations are interviewed within six months of delivery about exposures to 
influenza vaccine (seasonal and 2009 H1N1) and antiviral medications, as well as about 
potential confounding factors. The use of both cohort and case-control study designs is 
advantageous, given that each study design has its strengths and limitations and no one 
methodology is sufficient to determine if an exposure is safe during pregnancy.
VAMPSS investigators have addressed the issue of the difficulty in assessing safety in their 
study by setting up “safety thresholds” that specify when data will be reviewed by an 
independent advisory committee. An odds ratio of ≤1.0 with an upper 95% confidence 
bound of ≤4.0 may be defined by the committee as “no evidence of risk”, whereas, an odds 
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ratio of ≤1.0 with an upper 95% confidence bound of ≤2.0 may be defined as “evidence of 
relative safety” (Schatz et al., 2011).
Acetaminophen was also widely used during the pandemic to treat fever, and since the 
pandemic, additional data have become available regarding risks to the embryo or fetus after 
use of acetaminophen during pregnancy. In 2010, Feldkamp et al. reported data from the 
National Birth Defects Prevention Study that showed no increased risks with maternal 
acetaminophen exposure for each of over 50 birth defects (Feldkamp et al., 2010). Before 
the pandemic, some studies had shown an association between maternal acetaminophen use 
and asthma in childhood (Shaheen et al., 2002; Koniman et al., 2007; Persky et al., 2008; 
Rebordosa et al., 2008; Garcia-Marcos et al., 2009), although not all studies had identified 
an association (Kang et al., 2009). Two additional studies became available after the 
pandemic, but these have failed to quell the controversy over this issue. A study by 
Perzanowski et al. (2010) supported an association; maternal acetaminophen use was 
associated with current wheezing (risk ratio, 1.71; 95% CI, 1.20–2.42), with risk increasing 
as the number of days of acetaminophen use increased (Perzanowski et al., 2010). In 
contrast, a study by Bakkeheim et al. (2011) showed no association between prenatal 
acetaminophen use and asthma at age 10 years (Bakkeheim et al., 2011). In a recent review 
Scialli et al. concluded that data to support a causal association are currently inconclusive 
(Scialli et al., 2010).
Similar to the way the 2009 H1N1 pandemic raised questions about the safety of influenza 
medications and vaccines during pregnancy, the recent outbreak of pertussis in the United 
States has also raised the issue of safety of vaccination with the tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy. Pertussis (also 
known as whooping cough) is a respiratory illness caused by the bacteria Bordetella 
pertussis. Pertussis is transmitted easily between persons by coughing or sneezing while in 
close contact. In 2010, the state of California reported the highest number of cases of 
pertussis (9120) with onset in 2010 in 63 years and the highest rate (23.3 cases per 100,000) 
in 52 years. During 2010, nearly 10% of cases required hospitalization (55% were <3 
months of age and 72% were <6 months of age), and there were 10 deaths, 9 in infants <2 
months of age (California Department of Public Health, 2011).
Vaccination can reduce the risk for pertussis illness; however, infants <2 months of age 
account for the majority of pertussis cases, hospitalizations, and deaths, but are too young to 
be vaccinated (CDC, 2011b). Beginning in 2005, the Advisory Committee on Immunization 
Practices (ACIP), which provides advice and guidance to the CDC regarding vaccine-
preventable diseases, recommended “cocooning” (vaccination of mothers and other family 
members of newborn infants) as a strategy to protect infants from pertussis. However, this 
strategy has been challenging to implement on a large scale (Healy et al., 2009; Healy et al., 
2011). Given that transplacental maternal antibodies might protect infants from vaccine-
preventable disease, the ACIP recently considered Tdap vaccination during pregnancy as an 
option.
ACIP deliberations regarding Tdap vaccination during pregnancy addressed several issues 
including evidence related to the safety of Tdap vaccine during pregnancy, to the protection 
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of infants from pertussis from transplacental maternal antibodies, and to the possibility of 
interference with the infant’s immune response to their primary vaccination with diphtheria 
toxoid, tetanus toxoid, and acellular pertussis (DTaP) vaccination. For all of these issues, 
definitive data were lacking. Because prelicensure studies of Tdap vaccine had excluded 
pregnant women, available information on the safety of Tdap during pregnancy was limited 
to unpublished data from the Vaccine Adverse Event Reporting System and pharmaceutical 
company-sponsored pregnancy registries along with a few small published studies (Talbot et 
al., 2010; CDC, 2011b; Gall et al., 2011). However, the ACIP found the available data on 
safety to be reassuring. In addition, tetanus and diphtheria toxoid vaccines have been used 
widely during pregnancy throughout the world for the prevention of neonatal tetanus, and 
studies suggest that these vaccines are not teratogenic (Silveira et al., 1995; Czeizel and 
Rockenbauer, 1999). Although maternal vaccination with Tdap vaccine during pregnancy 
has not yet been shown to protect infants from pertussis, infants born to mothers who 
received Tdap vaccine before or during pregnancy have higher levels of anti-pertussis 
antibodies in cord blood, compared to infants born to unvaccinated mothers, suggesting that 
the infant will be protected (Gall et al., 2011; Leuridan et al., 2011). Whether maternal 
vaccination could blunt the infant’s immune response to vaccination against pertussis is also 
unknown; however, data suggest that blunting would not persist, given that maternal 
pertussis antibody levels decline quickly after birth, with a half-life of approximately six 
weeks (Van Savage et al., 1990; Healy et al., 2004; Van Rie et al., 2005; Hardy-Fairbanks et 
al., 2010). Based on a review of these data on the risks and benefits of Tdap vaccination 
during pregnancy, ACIP recommended that health care providers administer Tdap vaccine 
during pregnancy, preferably during the third or late second (after 20 weeks gestation) 
trimester (CDC, 2011b).
In conclusion, determining whether a medication or vaccine is “safe” for use during 
pregnancy is challenging. The mean time for a medication approved by the FDA since 1980 
and initially classified as having an undetermined risk by the Teratogen Information System 
to be assigned a more precise risk is 27 years (Adam et al., 2011). This lack of adequate 
information leaves pregnant women and their health care providers without the evidence 
base needed to guide decisions about treatment and prevention during pregnancy (Chambers 
et al., 2008). To remedy this predicament, more research is needed to understand causes of 
birth defects and other adverse outcomes. Understanding the basic mechanisms of 
teratogenesis is also essential. Careful consideration needs to be made as to when it is 
appropriate to include pregnant women in clinical trials (Chervenak and McCullough, 2011). 
Given that different study designs have strengths and limitations in identifying risks of 
exposures during pregnancy, complementary study designs (e.g., cohort and case-control 
studies) should be used to assess potential risks of exposures during pregnancy. Studies may 
benefit from criteria set in advance to define “safety”, similar to those defined by VAMPSS 
(Schatz et al., 2011). However, in the meantime, pregnant women, their health care 
providers, and public health professionals will need to continue to balance the benefits of 
medication or vaccine with the potential, but unknown, risks. More research is needed on 
how to communicate this complicated information of risks and benefits and the uncertainty 
of our current knowledge to pregnant women and their partners.
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